Drug Approval | December 20, 2021
WHO grants EUL for Covovax
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
Effectiveness of Covaxin against the Omicron variant is currently being studied
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Subscribe To Our Newsletter & Stay Updated
